Pharmacopeia's deal with Schering-Plough is one of the very few rich alliances in a technology area in which only Affymax has proven that it can attract significant big-company funding. Selectide's acquisition by Marion Merrell Dow raises questions about how much this technology can be partnered: many potentialpartners believe they can develop the technology on their own, or if they can't, want to use the start-up's libraries against all of their targets--a virtual acquisition. Real acquisition might be the best option.
You may also be interested in...
Just three years after its founding, Chinese cell therapy developer IASO Bio already has two assets in clinical development and the Nanjing firm has recently attracted $60m in financing. In an exclusive interview, its R&D head told Scrip that speed and partnerships are propelling Chinese developers on a trajectory to quickly catch up with the west in the emerging cell-therapy arena.
Updated guidance from England’s National Institute for Health and Care Excellence says two neurostimulation systems for treatment-resistant depression and epilepsy should only be used under special conditions. See what LivaNova’s VP of difficult-to-treat depression, Jonathan Walker, said about it here.